Literature DB >> 6847811

Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand.

J L Rouleau, K Chatterjee, T A Ports, M B Doyle, B Hiramatsu, W W Parmley.   

Abstract

To evaluate the influence of oral verapamil (80 and 120 mg) on angina threshold, coronary blood flow, myocardial oxygen consumption and left ventricular function, we subjected 13 patients with effort angina and fixed obstructive coronary artery disease to atrial pacing at progressively higher heart rates. After 120 mg of verapamil, the time to onset of angina and the heart rate at the onset of ST-segment depression increased by 18% (p less than 0.005) and 10% (p less than 0.001), respectively, without any change in the angina threshold (rate-pressure product at the onset of angina). The rate-pressure product, coronary blood flow and myocardial oxygen consumption were lower at rest and at pre-angina heart rates but not when the angina threshold was reached. Thus, the beneficial effect of verapamil was primarily due to decreased myocardial oxygen demand rather than to increased coronary blood flow. The decreased demand resulted from a lower arterial pressure at each pacing rate. In these patients without heart failure, left ventricular pump function did not deteriorate. This beneficial response was less with 80 mg of oral verapamil. These findings suggest that oral verapamil has a potential role in the management of patients with effort angina due to fixed obstructive coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847811     DOI: 10.1161/01.cir.67.1.94

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

2.  Effects of nicardipine on coronary blood flow, left ventricular inotropic state and myocardial metabolism in patients with angina pectoris.

Authors:  M F Rousseau; M F Vincent; P Cheron; G van den Berghe; A A Charlier; H Pouleur
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 4.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  Alterations in angina threshold with nifedipine during pacing induced angina.

Authors:  P H Kramer; K Chatterjee; A Schwartz; K Swedberg; J L Rouleau; D Curran; L Blevins; W W Parmley
Journal:  Br Heart J       Date:  1984-09

Review 6.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

7.  Beneficial effects of verapamil during metabolic acidosis in isolated perfused rat hearts.

Authors:  W Markiewicz; S S Wu; R Sievers; W W Parmley; T A Watters; T L James; C B Higgins; J Wikman-Coffelt
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 8.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.